Senate panel hits Sanofi payments
Sanofi SA contributed more than $5 million to two medical groups and a medical researcher that encouraged U.S. regulators to delay approval of a drug that would undercut the company's blockbuster blood-thinner Lovenox, according to a new report from the Senate Finance Committee. Letters to the FDA from the groups--the Society of Hospital Medicine and the North American Thrombosis Forum—and the researcher, Victor Tapson, a thrombosis expert at Duke University, said that generic versions of Lovenox, a fast-acting anticlotting medicine, might not be as safe as the brand-name drug, according to the report. The letters didn't mention financial ties to Sanofi.
- Half of All Primary Care, Internal Medicine Jobs Unfilled in 2013
- How Digital Strategy Shapes Patient Engagement at Boston Children's Hospital
- CNO on Hospital Redesign: 'You Can't Over-Communicate'
- CFO Exchange: Smartphones Poised to Disrupt Healthcare, Says Topol
- Some Cancer Hospitals' Quality Data Will Soon Be Public
- CA Powers Up $80M HIE to 'Create Value in the Data'
- TJC Warns Hospitals of Deadly Medical Tubing Mistakes
- PA Ranks See 'Phenomenal Growth,' Lack of Diversity
- 3 Traits Personality Assessments Can't Reveal
- The secret committee behind our soaring healthcare costs